<DOC>
	<DOC>NCT01507311</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current OHA (oral hypoglycaemic agent) treatment with stable dose for at least six months BMI (Body Mass Index) between 24 and 35 kg/m^2 (both inclusive) Fasting plasma glucose between 6 and 15 mmol/l (both inclusive) AntiGAD (glutamic acid decarboxylase) negative Known or suspected allergy to trial product or related products Receipt of any investigational drug within three months prior to this trial Recurrent severe hypoglycaemia as judged by the investigator Cardiac disease or any clinically significant abnormal ECG (electrocardiogram) Use of any drug (except oral hypoglycaemic agents (OHAs)) which in the investigator's opinion could interfere with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides) Liver or renal disease</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>